Generics in Asia-Pacific
Generics in Asia-Pacific
SUMMARY
Generics in Asia-Pacific industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2015-19, and forecast to 2024). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
KEY HIGHLIGHTS
SUMMARY
Generics in Asia-Pacific industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2015-19, and forecast to 2024). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
KEY HIGHLIGHTS
- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The Asia-Pacific generics market had total revenues of $129.9bn in 2019, representing a compound annual growth rate (CAGR) of 7.3% between 2015 and 2019.
- Market consumption volume increased with a CAGR of 2.6% between 2015 and 2019, to reach a total of 76.8% in 2019.
- China accounted for 53.7% of the value of the Asia-Pacific market in the 2019, followed by Japan and India with 21.1% and 12.7%, respectively.
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Asia-Pacific
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Asia-Pacific
- Leading company profiles reveal details of key generics market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Asia-Pacific generics market with five year forecasts by both value and volume
- What was the size of the Asia-Pacific generics market by value in 2019?
- What will be the size of the Asia-Pacific generics market in 2024?
- What factors are affecting the strength of competition in the Asia-Pacific generics market?
- How has the market performed over the last five years?
- How large is Asia-Pacific’s generics market in relation to its regional counterparts?
1 EXECUTIVE SUMMARY
1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive Landscape
2 MARKET OVERVIEW
2.1. Market definition
2.2. Market analysis
3 MARKET DATA
3.1. Market value
3.2. Market volume
4 MARKET SEGMENTATION
4.1. Geography segmentation
5 MARKET OUTLOOK
5.1. Market value forecast
5.2. Market volume forecast
6 FIVE FORCES ANALYSIS
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 COMPETITIVE LANDSCAPE
7.1. Who are the leading players?
7.2. What are the strengths of the leading players?
7.3. Has there been any significant recent M&A activity?
7.4. How has the outbreak of COVID-19 impacted leading players?
8 COMPANY PROFILES
8.1. Teva Pharmaceutical Industries Limited
8.2. Mylan N.V.
8.3. Sun Pharmaceutical Industries Ltd
8.4. Pfizer Inc.
9 APPENDIX
9.1. Methodology
9.2. About MarketLine
1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive Landscape
2 MARKET OVERVIEW
2.1. Market definition
2.2. Market analysis
3 MARKET DATA
3.1. Market value
3.2. Market volume
4 MARKET SEGMENTATION
4.1. Geography segmentation
5 MARKET OUTLOOK
5.1. Market value forecast
5.2. Market volume forecast
6 FIVE FORCES ANALYSIS
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 COMPETITIVE LANDSCAPE
7.1. Who are the leading players?
7.2. What are the strengths of the leading players?
7.3. Has there been any significant recent M&A activity?
7.4. How has the outbreak of COVID-19 impacted leading players?
8 COMPANY PROFILES
8.1. Teva Pharmaceutical Industries Limited
8.2. Mylan N.V.
8.3. Sun Pharmaceutical Industries Ltd
8.4. Pfizer Inc.
9 APPENDIX
9.1. Methodology
9.2. About MarketLine
LIST OF TABLES
Table 1: Asia-Pacific generics market value: $ billion, 2015-19
Table 2: Asia-Pacific generics market volume: % of total pharma, 2015-19
Table 3: Asia-Pacific generics market geography segmentation: $ billion, 2019
Table 4: Asia-Pacific generics market value forecast: $ billion, 2019-24
Table 5: Asia-Pacific generics market volume forecast: % of total pharma, 2019-24
Table 6: Teva Pharmaceutical Industries Limited: key facts
Table 7: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Limited: Key Employees
Table 9: Mylan N.V.: key facts
Table 10: Mylan N.V.: Annual Financial Ratios
Table 11: Mylan N.V.: Key Employees
Table 12: Sun Pharmaceutical Industries Ltd: key facts
Table 13: Sun Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 14: Sun Pharmaceutical Industries Ltd: Key Employees
Table 15: Pfizer Inc.: key facts
Table 16: Pfizer Inc.: Annual Financial Ratios
Table 17: Pfizer Inc.: Key Employees
Table 18: Pfizer Inc.: Key Employees Continued
Table 1: Asia-Pacific generics market value: $ billion, 2015-19
Table 2: Asia-Pacific generics market volume: % of total pharma, 2015-19
Table 3: Asia-Pacific generics market geography segmentation: $ billion, 2019
Table 4: Asia-Pacific generics market value forecast: $ billion, 2019-24
Table 5: Asia-Pacific generics market volume forecast: % of total pharma, 2019-24
Table 6: Teva Pharmaceutical Industries Limited: key facts
Table 7: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Limited: Key Employees
Table 9: Mylan N.V.: key facts
Table 10: Mylan N.V.: Annual Financial Ratios
Table 11: Mylan N.V.: Key Employees
Table 12: Sun Pharmaceutical Industries Ltd: key facts
Table 13: Sun Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 14: Sun Pharmaceutical Industries Ltd: Key Employees
Table 15: Pfizer Inc.: key facts
Table 16: Pfizer Inc.: Annual Financial Ratios
Table 17: Pfizer Inc.: Key Employees
Table 18: Pfizer Inc.: Key Employees Continued
LIST OF FIGURES
Figure 1: Asia-Pacific generics market value: $ billion, 2015-19
Figure 2: Asia-Pacific generics market volume: % of total pharma, 2015-19
Figure 3: Asia-Pacific generics market geography segmentation: % share, by value, 2019
Figure 4: Asia-Pacific generics market value forecast: $ billion, 2019-24
Figure 5: Asia-Pacific generics market volume forecast: % of total pharma, 2019-24
Figure 6: Forces driving competition in the generics market in Asia-Pacific, 2019
Figure 7: Drivers of buyer power in the generics market in Asia-Pacific, 2019
Figure 8: Drivers of supplier power in the generics market in Asia-Pacific, 2019
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Asia-Pacific, 2019
Figure 10: Factors influencing the threat of substitutes in the generics market in Asia-Pacific, 2019
Figure 11: Drivers of degree of rivalry in the generics market in Asia-Pacific, 2019
Figure 1: Asia-Pacific generics market value: $ billion, 2015-19
Figure 2: Asia-Pacific generics market volume: % of total pharma, 2015-19
Figure 3: Asia-Pacific generics market geography segmentation: % share, by value, 2019
Figure 4: Asia-Pacific generics market value forecast: $ billion, 2019-24
Figure 5: Asia-Pacific generics market volume forecast: % of total pharma, 2019-24
Figure 6: Forces driving competition in the generics market in Asia-Pacific, 2019
Figure 7: Drivers of buyer power in the generics market in Asia-Pacific, 2019
Figure 8: Drivers of supplier power in the generics market in Asia-Pacific, 2019
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Asia-Pacific, 2019
Figure 10: Factors influencing the threat of substitutes in the generics market in Asia-Pacific, 2019
Figure 11: Drivers of degree of rivalry in the generics market in Asia-Pacific, 2019